je.st
news
Tag: treatment
Novartis buys remaining rights to GSK treatment in deal up to $1 billion
2015-08-21 09:12:45| Biotech - Topix.net
Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's GlaxoSmithKline. Basel-based Novartis will make an initial upfront payment of $300 million to GSK for the acquisition of the compound and a further $200 million payable following the start of a phase III study in MS by Novartis.
Tags: to
rights
treatment
deal
Water treatment facility in Rio Bravo, Texas.
2015-08-21 01:43:43| Waste Management - Topix.net
The state of Texas should have done more to protect the safety of drinking water for two small border communities in Webb County, defense lawyers argued Thursday in the criminal trial for two former water treatment plant employees. Former Webb County employees Johnny Amaya and Luis Camacho are accused of lying about quality of drinking water treated at the Rio Bravo Water Treatment Plant, which serves the neighboring towns of Rio Bravo and El Cenizo.
Tags: water
treatment
texas
rio
New seed treatment, high-tech corn coming to market
2015-08-19 21:25:00| Corn & Soybean Digest
DuPont Pioneer launches range of new tools, including new seed treatment package for corn, Lumivia. Also included is a line-up of traited corn products, called Qrome, which combines two traits into a single event. read more
Tags: market
coming
treatment
seed
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
2015-08-18 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Doctors: Various factors figure into Carter cancer treatment
2015-08-13 12:09:52| Apparel - Topix.net
On Wednesday, Aug. 12, 2015, Carter announced he has cancer and will undergo treatment at an Atlanta hospital. . FILE - In this July 10, 2015, file photo, former President Jimmy Carter is seen in Philadelphia.
Tags: treatment
figure
factors
cancer
Sites : [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] next »